DiaMedica Therapeutics In... (DMAC)
DiaMedica Therapeutics Statistics
Share Statistics
DiaMedica Therapeutics has 42.76M shares outstanding. The number of shares has increased by 12.65% in one year.
| Shares Outstanding | 42.76M |
| Shares Change (YoY) | 12.65% |
| Shares Change (QoQ) | 0.03% |
| Owned by Institutions (%) | 13.05% |
| Shares Floating | 24M |
| Failed to Deliver (FTD) Shares | 78 |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 175.55K, so 0.41% of the outstanding shares have been sold short.
| Short Interest | 175.55K |
| Short % of Shares Out | 0.41% |
| Short % of Float | 0.73% |
| Short Ratio (days to cover) | 3.88 |
Valuation Ratios
The PE ratio is -4.77 and the forward PE ratio is -7.53. DiaMedica Therapeutics's PEG ratio is -0.31.
| PE Ratio | -4.77 |
| Forward PE | -7.53 |
| PS Ratio | 0 |
| Forward PS | 6.9 |
| PB Ratio | 1.81 |
| P/FCF Ratio | -4.93 |
| PEG Ratio | -0.31 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for DiaMedica Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.27, with a Debt / Equity ratio of 0.01.
| Current Ratio | 19.27 |
| Quick Ratio | 19.27 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.78 |
| Cash Flow / Debt | -46.82 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.38% and return on capital (ROIC) is -41.42%.
| Return on Equity (ROE) | -0.38% |
| Return on Assets (ROA) | -0.36% |
| Return on Capital (ROIC) | -41.42% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1,076,722.22 |
| Employee Count | 18 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 43K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 112.05% in the last 52 weeks. The beta is 1.45, so DiaMedica Therapeutics's price volatility has been higher than the market average.
| Beta | 1.45 |
| 52-Week Price Change | 112.05% |
| 50-Day Moving Average | 5.83 |
| 200-Day Moving Average | 4.31 |
| Relative Strength Index (RSI) | 59.32 |
| Average Volume (20 Days) | 94.59K |
Income Statement
| Revenue | n/a |
| Gross Profit | -30K |
| Operating Income | -21.27M |
| Net Income | -19.38M |
| EBITDA | -19.31M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.6 |
Balance Sheet
The company has 4.54M in cash and 400K in debt, giving a net cash position of 4.14M.
| Cash & Cash Equivalents | 4.54M |
| Total Debt | 400K |
| Net Cash | 4.14M |
| Retained Earnings | -115.56M |
| Total Assets | 52.52M |
| Working Capital | 46.47M |
Cash Flow
In the last 12 months, operating cash flow was -18.73M and capital expenditures -24K, giving a free cash flow of -18.75M.
| Operating Cash Flow | -18.73M |
| Capital Expenditures | -24K |
| Free Cash Flow | -18.75M |
| FCF Per Share | -0.58 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DMAC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -9.22% |
| FCF Yield | -6.74% |
Analyst Forecast
The average price target for DMAC is $7, which is 7.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 7.5% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Nov 15, 2018. It was a backward split with a ratio of 1:20.
| Last Split Date | Nov 15, 2018 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | 31.16 |
| Piotroski F-Score | 3 |